Building Bridges Between the World's Two Largest Biopharma Markets
Six Ways We Help You Win
Out-Licensing & In-Licensing
We facilitate high-value licensing transactions between Chinese biotechs and global pharmaceutical companies — structuring deals, aligning interests, and accelerating the path from term sheet to signed agreement. Our network includes 250+ Chinese clients with 400+ projects actively seeking global partners.
Cross-Border Collaboration
Beyond licensing, we facilitate strategic alliances, co-development agreements, and joint ventures across the US-China corridor. We navigate cultural, regulatory, and business norms on both sides to ensure partnerships are built for durability.
Capital Acquisition
We connect Chinese biotech companies and US firms with pre-screened venture capital and strategic investors. Our relationships span 10+ active US-based VC firms with direct interest in cross-border biopharma assets.
Talent Acquisition
Scientific and commercial talent is a critical bottleneck for cross-border programs. We provide executive search and recruitment support — drawing on a network of 16,000+ LinkedIn connections and 30+ WeChat professional groups — to place the right people on both sides of the Pacific.
R&D Enablement (CRO/CDMO)
Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape to match clients with partners whose capabilities, capacity, and culture align with their program requirements.
Market Research & China Insights
Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports and ongoing intelligence — including BioLink Weekly — provide the depth and currency needed to make confident strategic decisions.
Why Partners Choose BioRich
Global Reach
250+ clients across 2 continents
Our dual-shore presence — headquartered in Princeton, NJ with deep roots in China's biopharma ecosystem — gives us authentic access and credibility on both sides of the Pacific. We operate in the time zones, languages, and professional networks where deals actually happen.
Extensive Networking
16,000+ LinkedIn connections · 30+ WeChat groups
Our founder maintains more than 16,000 LinkedIn connections and manages over 30 WeChat professional groups with 500 members each — forming one of the most extensive personal networks in US-China biopharma. This network is our most valuable asset and is put to work on every engagement.
Sector Expertise
30+ years across BMS, Wyeth, WuXi, CrownBio
With three decades spanning oncology and CNS research at Bristol Myers Squibb and Wyeth, followed by business development roles at WuXi AppTec and CrownBio, our team brings a rare combination of scientific depth, deal experience, and cross-cultural fluency.
Customized Solutions
5 term sheets in 24 months
We do not offer off-the-shelf advisory packages. Every engagement begins with a thorough assessment of the client's specific assets, goals, and constraints. Our approach is tailored to maximize the probability of a successful outcome — not to maximize billable hours.
Meet the Team
John Xu
MD, MBA, MS
Founder & President, BioRich International
President, North America Pharmaceutical Professional Alliance (NAPPA)
John Xu brings over 30 years of experience spanning pharmaceutical research, business development, and cross-border deal facilitation. His career began in drug discovery at two of the industry's most storied organizations — Wyeth and Bristol Myers Squibb — accumulating 14 years combined (1996 – 2010) before transitioning to business development at WuXi AppTec and CrownBio.
John then spent seven years in licensing roles at Abpro, Jemincare, and Hopstem before becoming an independent BD consultant in 2023, leading BioRich International. He also founded NAPPA, the North America Pharmaceutical Professional Alliance.
Career Timeline
Ready to Work Together?
Reach out to discuss how BioRich International can support your next partnership, deal, or strategic initiative.
Contact Us